BMS preps filings for leukaemia maintenance therapy CC-486

Brisk trade in risky three-drug 'bet' option after BMS/Celge...

Bristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and the focus has shifted on to whether Celgene shareholders will

BMS' Opdivo/Yervoy combo hits a snag in adjuvant melanoma

$74bn BMS/Celgene merger finally cleared by competition regu...

Bristol-Myers Squibb and Celgene’s merger looks set to close tomorrow after US competition regulators finally gave the $74 billion deal the go-ahead.

FDA decision on Opdivo/Yervoy in liver cancer due next March

BMS gets a much-needed win with Opdivo in first-line lung ca...